Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti‐angiogenic therapy: A report from the children's oncology group phase I consortium

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|1|45-51

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.1, 2015-01, pp. : 45-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 3, 2015-03 ,pp. : 440-444

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 751-758

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 10, 2015-10 ,pp. : 1717-1724

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-angiogenic therapy in breast cancer

By Atiqur Rahman M.   Toi M.  

Biomedicine and Pharmacotherapy, Vol. 57, Iss. 10, 2003-12 ,pp. : 463-470

Elsevier

Access to resources Recommend Favorite

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1562-1566

John Wiley & Sons Inc

Access to resources Recommend Favorite